retatrutide peptide peptide sciences Peptide: Triple Agonist Mechanism, Research Benefits, and Comparisons Retatrutide - Wikipedia

Where the GLP-1 MDL stands now As of March 2026, the GLP-1 MDL is in the expert discovery phase

Its clinical development was halted, so there is no completed pivotal trial, no approved label, no reviewed dose, and no regulatory safety determination

The program, part of the Inflation Reduction Act, is a signature achievement of the Biden administration

The former mainly include sulfonylureas, glinides, dipeptidyl peptidase-IV inhibitors (DPP-4i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the latter mainly include biguanides, thiazolidinediones (TZDs), -glucosidase inhibitors, and sodium-glucose cotransport-2 inhibitors (SGLT-2i)